Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease

Inflammatory Bowel Diseases

Volumn 10, Issue 6, 2004, Pages 745-750

  Lamireau, Thierry ^a   Cézard, Jean Pierre ^a   Dabadie, Alain ^a   Goulet, Olivier ^a   Lachaux, Alain ^a   Turck, Dominique ^a   Maurage, Chantal ^a   Morali, Alain ^a   Sokal, Etienne ^a   Belli, Dominique ^a   Stoller, Joaquim ^a   Cadranel, Samy ^a   Ginies, Jean Louis ^a   Viola, Sheila ^a   Huet, Frédéric ^a   Languepin, Jane ^a   Lenaerts, Catherine ^a   Bury, Françoise ^a   Sarles, Jacques ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Children; Crohn's disease; Infliximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PARACETAMOL; PREDNISOLONE;

ADOLESCENT; ANGINA PECTORIS; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARENTERAL NUTRITION; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SCORING SYSTEM; SHIVERING; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TACHYCARDIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; EUROPE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MEDICAL RECORDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9144234882     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200411000-00008     Document Type: Article

References (36)

1. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
2. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991;6:192-219.
3. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25:699-717.
4. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
5. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
6. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466.
7. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
8. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
9. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30: 1443-1453.
10. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
11. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15-25.
12. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
13. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
14. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
16. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
17. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
18. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111.
19. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2003;36:632-636.
20. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838.
21. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002;8:237-243.
22. de Ridder L, Escher JC, Taminiau JA. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients] Ned Tijdschr Geneeskd. 2002;146:1879-1883.
23. Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003;17:387-393.
24. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
25. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
26. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
27. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
28. Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001;7: 34-37.
29. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-1414.
30. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13 (Suppl 4):16-22; discussion 38.
31. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
32. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324.
33. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
34. Reichardt P, Dahnert I, Tiller G, et al. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Pediatr. 2002;161: 281-283.
35. Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003;15:351-354.
36. McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol. 2003;36:411-413.